Finch Therapeutics Group earnings missed by 0.15, revenue fell short of estimates
FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Under 62% of Finch Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Finch Therapeutics Group pink sheet suggests that many investors are alarmed at this time. Finch Therapeutics' investing sentiment shows overall attitude of investors towards Finch Therapeutics Group.
Finch |
Finch Therapeutics Group earnings missed by 0.15, revenue fell short of estimates
Read at investing.com
Finch Therapeutics Fundamental Analysis
We analyze Finch Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Finch Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Finch Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Finch Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics with similar companies.
Peers
Finch Therapeutics Related Equities
VRAX | Virax Biolabs | 27.98 | ||||
KPRX | Kiora Pharmaceuticals | 7.44 | ||||
CCCC | C4 Therapeutics | 4.34 | ||||
LGVN | Longeveron LLC | 4.19 | ||||
RNXT | RenovoRx | 1.47 | ||||
REVB | Revelation Biosciences | 1.54 | ||||
IKNA | Ikena Oncology | 1.78 | ||||
CELC | Celcuity LLC | 3.30 | ||||
HOWL | Werewolf Therapeutics | 3.57 | ||||
GLUE | Monte Rosa | 3.91 | ||||
STOK | Stoke Therapeutics | 4.09 | ||||
NTRB | Nutriband | 4.14 | ||||
EWTX | Edgewise Therapeutics | 4.18 | ||||
QNRX | Quoin Pharmaceuticals | 4.29 | ||||
DSGN | Design Therapeutics | 5.26 | ||||
XLO | Xilio Development | 8.18 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |